Companies › Intervene Immune
1 active drug program in 1 registered trial: 1 Phase 2; Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TRIIM Treatment Combination of somatropin (recombinant human growth hormone), metformin, and DHEA | GH1, AMPK | Phase 2 | Epigenetic Aging | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04375657 | TRIIM Treatment | Phase 2 | Epigenetic Aging | Other | Dec 2025 |
Kexing Biopharm Xiamen Amoytop Biotech Changchun GeneScience Pharmaceutical
Serum Life Science Europe Distribuidora Biolife SA de CV Circul'Egg Biosolution Photozig
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.